FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

Until recently in the United States, no products were approved for second‐line treatment of advanced urothelial carcinoma. On May 18, 2016, the U.S. Food and Drug Administration approved atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2017-06, Vol.22 (6), p.743-749
Hauptverfasser:	Ning, Yang‐Min, Suzman, Daniel, Maher, V. Ellen, Zhang, Lijun, Tang, Shenghui, Ricks, Tiffany, Palmby, Todd, Fu, Wentao, Liu, Qi, Goldberg, Kirsten B., Kim, Geoffrey, Pazdur, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Atezolizumab Bladder cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - epidemiology Carcinoma, Transitional Cell - pathology Drug Approval Female Humans Immunotherapy Locally advanced or metastatic urothelial carcinoma Male Middle Aged Platinum - therapeutic use Platinum‐containing chemotherapy Regulatory Issues: FDA Response Evaluation Criteria in Solid Tumors Risk Assessment Treatment Outcome United States United States Food and Drug Administration Urologic Neoplasms - drug therapy Urologic Neoplasms - epidemiology Urologic Neoplasms - pathology Urothelium - drug effects Urothelium - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!